ArticleTheranostics2017
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06558682 (Disitamab Vedotin Combined With Cisplatin for Neoadjuvant Therapy in Locally Advanced Cervical Cancer), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Disitamab Vedotin Combined With Cisplatin for Neoadjuvant Therapy in Locally Advanced Cervical Cancer: a Prospective, Single-arm Clinical Trial
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Pathogenic Mechanisms in Cervical Cancer: Energy Metabolism, Hypoxia and Therapy.Life (Basel, Switzerland) · 2026Review
- Combined Assessment of EZH2 and EGFR as Potential Diagnostic Biomarkers for Epithelial Ovarian Tumors: Bioinformatics Analysis and Clinical Validation.International journal of women's health · 2026Article
- RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR-targeted therapies.Molecular oncology · 2025Article
- Prognostic value of HER2 expression in cervical adenocarcinoma: A retrospective cohort study.Oncology letters · 2025Article
- Unveiling the RKIP and EGFR Inverse Relationship in Solid Tumors: A Case Study in Cervical Cancer.Cancers · 2024Article
- Effect of HPV Oncoprotein on Carbohydrate and Lipid Metabolism in Tumor Cells.Current cancer drug targets · 2024Review
- Changes in HER3 expression profiles between primary and recurrent gynecological cancers.Cancer cell international · 2023Article
- An integrative approach toward identification and analysis of therapeutic targets involved in HPV pathogenesis with a focus on carcinomas.Cancer biomarkers : section A of Disease markers · 2023Article
- Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.BMC medical genomics · 2022Article
- Multi-Omics Integration-Based Prioritisation of Competing Endogenous RNA Regulation Networks in Small Cell Lung Cancer: Molecular Characteristics and Drug Candidates.Frontiers in oncology · 2022Article
- A four immune-related long noncoding RNAs signature as predictors for cervical cancer.Human cell · 2022Article
- Review
- IL-17A and IL-17F orchestrate macrophages to promote lung cancer.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems.Drug delivery and translational research · 2020Article
- Near-IR emissive rare-earth nanoparticles for guided surgery.Theranostics · 2020Review
- Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA.Cell death and differentiation · 2019Article
- Article
- Establishment, molecular and biological characterization of HCB-514: a novel human cervical cancer cell line.Scientific reports · 2019Article
- Regulation of Cellular Metabolism by High-Risk Human Papillomaviruses.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent HPV infection alone is not sufficient for cervical cancer development, which requires additional molecular alterations for tumor progression and metastasis ultimately leading to a lethal disease. In this study, we performed a comprehensive analysis of HER family receptor alterations in cervical adenocarcinoma. We detected overexpression of HER protein, mainly HER2, which was an independent prognostic marker for these patients. By using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.